<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694405</url>
  </required_header>
  <id_info>
    <org_study_id>CT17_CIRN24_Achieve01</org_study_id>
    <nct_id>NCT03694405</nct_id>
  </id_info>
  <brief_title>Adolescent MenACWY Booster Study</brief_title>
  <official_title>A Randomized, Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada; a Canadian Immunization Research Network (CIRN) Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Center for Vaccinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Centre for Disease Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Immunization Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to confirm non-inferiority of the three MenACWY vaccines (Menveo, Menactra or
      Nimenrix) in adolescents, and to identify whether the number of previous doses of MenC
      influences the response to the MenACWY vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive one of the three doses of licensed MenACWY as a
      booster dose in adolescents. Serology will be collect at 3 time points; prior to the booster
      dose and 1 month and 1 year post-vaccination to measure antibody levels. The participants are
      healthy students in grades 7-9 who have not received their MenACWY vaccine yet and received
      their routine infant MenC vaccines per previous Canadian schedules.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1 = 3 prior doses of MenC vaccine (Alberta), Group 2 = 2 prior doses of MenC vaccine (British Columbia), Group 3 = 1 prior dose of MenC vaccine (Nova Scotia). Group A = Menveo (MenACWY-CRM), Group B = Menactra (MenACWY-DT), Group C = Nimenrix (MenACWY-TT)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1-year post-MenACWY booster between groups with differing priming schedules</measure>
    <time_frame>1 year following MenACWY adolescent booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1-year post-MenACWY booster between differing vaccines</measure>
    <time_frame>1 year following MenACWY adolescent booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1 month post-MenACWY booster between groups with differing MenC priming schedules.</measure>
    <time_frame>1 month following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1 month post-MenACWY booster between groups with different MenACWY vaccines</measure>
    <time_frame>1 month following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis to determine effects of different MenACWY vaccines in subjects primed with different MenC schedules at 1 month and 1 year post-MenACWY booster</measure>
    <time_frame>1 month and 1 year following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis to determine effects of different MenC priming schedules in subjects receiving different MenACWY booster immunizations at 1 month and 1 year post-MenACWY booster</measure>
    <time_frame>1 month and 1 year following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirm safety of MenACWY conjugate vaccines</measure>
    <time_frame>Up to 1 month post-vaccine</time_frame>
    <description>Adverse events as reported by study participants</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Meningococcal Disease, Invasive</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>Booster vaccination with MenACWY-CRM</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 3A</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-DT</intervention_name>
    <description>Booster vaccination with MenACWY-DT</description>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_label>Group 3B</arm_group_label>
    <other_name>Menactra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-TT</intervention_name>
    <description>Booster vaccination with MenACWY-TT</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 3C</arm_group_label>
    <other_name>Nimenrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

        All the following need to be fulfilled:

          1. Healthy adolescent

          2. Previous receipt of appropriate MenC vaccine according to the relevant provincial
             schedule (see above)

          3. Parent/legal guardian has given informed consent OR participant has given consent (if
             participant demonstrates capacity to consent)

          4. Participant has given consent (as above) OR assent.

        EXCLUSION CRITERIA

        The participant may not enter the trial if ANY of the following apply:

          1. Has already received any doses of MenACWY vaccine at any age

          2. Previous confirmed or suspected meningococcal disease

          3. Close contact with an individual with laboratory-confirmed N. meningitidis in prior 12
             months

          4. Previous allergic reaction to a component of any of the 3 vaccines

          5. Serious chronic or progressive disease

          6. Confirmed/suspected immunodeficiency

          7. Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral
             prednisolone &gt;0.5mL/kg/day or intravenous glucocorticoid steroid). Nasal, topical or
             inhaled steroids are allowed

          8. Administration of immunoglobulins within the prior 12 months and/or any blood products
             planned during the study period

          9. Pregnancy (based on history from adolescent and parent/legal guardian)

         10. Any other significant disease or disorder which, in the opinion of the Investigator,
             may either put the participants at risk because of participation in the trial, or may
             influence the result of the trial, or the participant's ability to participate in the
             trial.

        TEMPORARY EXCLUSION CRITERIA If the adolescent has a temperature ≥ 38°C, then vaccination
        (and blood sampling if due to occur at same visit) will be postponed until resolution of
        fever.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Sadarangani, BM BCh DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Cosgrove</last_name>
    <phone>16048752669</phone>
    <email>acosgrove@bcchr.ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Research Institute, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joslyn Gray</last_name>
      <email>Joslyn.Gray@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Otto Vanderkooi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Center, BC Children's Hospital Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Cosgrove</last_name>
      <email>acosgrove@bcchr.ubc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Mutch</last_name>
      <email>Jill.Mutch@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Joanne Langley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MenACWY</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

